In April 2017, the FDA strengthened warnings and contraindications around codeine- and tramadol-containing products as a result of a review of adverse events from 1969 to May 2015. This podcast reviews details of these warnings and contraindications.
Rabiah Dys, PharmD
Division Vice President
Clinical Program Development, CPS
Valerie Sheehan, PharmD
Director, Clinical Program Development, CPS